Asahi Kasei Pharma announces that Teribone™ 28.2 µg subcutaneous autoinjector (generic name: teriparatide acetate) for the treatment of osteoporosis with high risk of fracture has been listed on Japan’s National Health Insurance (NHI) drug price standard today. The market launch of the product is scheduled for December 11, 2019.

The Teribone™ 28.2 µg subcutaneous autoinjector adds a new formulation option in addition to the conventional vial formulation of Teribone™ 56.5 µg subcutaneous injection*.

Teribone™ 28.2 µg subcutaneous autoinjector is designed to be easily used even by elderly patients, with a simple two-step process of taking off the cap, and pressing the injector point against the skin at the appropriate location. Because the patient doesn’t necessarily need to see the needle, which is hidden in the safety needle cover, a reduction of anxiety is expected. Being a single-use disposable product, it is hygienic and requires no reattachment of a new needle. Needle stick injuries are prevented as the needle is hidden inside the locked safety needle cover after injection.

Asahi Kasei Pharma believes that it can make a significant contribution to the treatment of osteoporosis by providing this safe, reliable and convenient autoinjector as a new formulation option.

• *The vial formulation of Teribone™ 56.5 µg subcutaneous injection is not approved for self-injection at home.

Product outline

Product name

Teribone™ 28.2 µg subcutaneous autoinjector

Generic name

Teriparatide acetate

Indication

Osteoporosis with high risk of fracture

Dosage and administration

For adults, ordinarily administered in a single 28.2 µg injection twice a week (one injection a day) for up to 24 months.

Manufacture and sale

Asahi Kasei Pharma Corp.

Approval

September 20, 2019

NHI price listing

November 27, 2019

Launch of sale

December 11, 2019

NHI price

¥6,018 per kit of 28.2 µg